Filing identity and reporting period
Important discrepancy: The supplied metadata identifies Lite Strategy, Inc. and 2015 Q2, but the filing text is MEI Pharma, Inc.’s Form 10-Q for the quarter ended December 31, 2016 (fiscal second quarter 2017). This summary follows the filing text; verify the intended company and period.
MEI Pharma is a clinical-stage oncology company. Its principal programs are Pracinostat, licensed to Helsinn, and internally developed candidates ME-401 and ME-344. Financial statements are unaudited.
Financial results and liquidity
| Metric | Three months ended Dec. 31, 2016 | Six months ended Dec. 31, 2016 | Prior-year comparable period |
|---|---|---|---|
| Revenue | $17.2 million | $18.3 million | None reported in 2015 |
| Operating income (loss) | $11.8 million | $7.5 million | Losses of $5.1 million and $9.8 million, respectively |
| Net income (loss) | $11.9 million | $7.6 million | Losses of $5.1 million and $9.7 million, respectively |
| Basic and diluted EPS | $0.32 | $0.21 | Losses of $0.15 and $0.28 per share, respectively |
| Operating cash flow | Not separately presented | $5.0 million provided | $10.0 million used in the six-month period |
- Quarterly operating margin was approximately 68.7%; six-month operating margin was approximately 41.0%. These unusually high margins reflect the recognition of Helsinn license revenue, not recurring product sales.
- At December 31, 2016, cash and cash equivalents were $15.1 million and short-term investments were $40.1 million, totaling $55.2 million. Total assets were $58.2 million; current liabilities were $3.3 million. No debt is reported on the balance sheet.
- Six-month investing cash outflow was $5.0 million, principally net purchases of short-term U.S. government securities. Financing cash inflow was $4.2 million from Helsinn’s equity investment.
- Common shares outstanding were 36.8 million at December 31, 2016, up from 34.2 million at June 30, 2016.
Material changes and significant agreements
- Revenue and the swing to profit were driven mainly by the Helsinn agreement: MEI recognized $17.1 million of license revenue after transfer of Pracinostat technology and data. The prior-year periods had no revenue.
- Helsinn paid a $15.0 million upfront fee in August 2016. A further $5.0 million was due upon the earlier of first-patient dosing in the planned Phase III AML trial or March 1, 2017. MEI is also eligible for up to $444 million in regulatory and sales milestones and tiered royalties; these amounts are contingent, not assured.
- MEI issued Helsinn Investment Fund 2,616,431 shares for $5.0 million. The filing allocated $788,000 of the equity transaction’s value difference as additional consideration related to the license revenue elements.
- Research and development expense fell to $3.3 million for the six months, from $6.0 million, partly because Helsinn assumed primary responsibility for funding Pracinostat development and because MEI revised estimates for clinical-trial costs by $1.9 million. General and administrative expense rose to $4.7 million from $3.8 million.
Outlook, risks, and contingencies
- Management expects operating losses and negative operating cash flows for the foreseeable future, but believes the $55.2 million of cash, cash equivalents, and short-term investments will fund operations through at least fiscal 2018. It anticipates needing future capital transactions to continue development.
- Management reported FDA Breakthrough Therapy Designation for Pracinostat plus azacitidine in certain newly diagnosed AML patients and agreement with FDA on the proposed Phase III design. A Phase II Pracinostat study in high- and very-high-risk MDS was expected to begin enrollment in calendar Q2 2017, with costs shared equally with Helsinn.
- ME-401’s Phase Ib study in recurrent CLL or follicular non-Hodgkin lymphoma was actively dosing; interim data were expected in calendar Q2 2017. ME-344’s investigator-sponsored breast cancer study was actively dosing; interim data were expected in the second half of calendar 2017.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, dependence on Helsinn and other counterparties, financing needs, commercialization and market-acceptance challenges, and intellectual-property risks. The company reported no material risk-factor changes from its 2016 annual report.
- Potential obligations include up to $75.2 million of S*Bio clinical, regulatory, and sales milestones if specified conditions are met; $700,000 was accrued for potential future payments at December 31, 2016. The Pracinostat Phase III trigger could also create an initial $700,000 S*Bio payment. Office lease payments totaled $172,000 through June 30, 2017.
- MEI recorded no income tax provision for the six-month period, citing tax loss carryforwards. It stated that it had no going-concern issues. Management said disclosure controls were effective and reported no legal proceedings.
Important facts for investors to verify
- Confirm the intended issuer and reporting period, given the metadata mismatch with the filing.
- Check whether the $5.0 million Helsinn payment was triggered or received, and review subsequent disclosures on trial start, reimbursements, milestones, and royalties.
- Assess whether reported profit and positive operating cash flow are sustainable; results depend heavily on a one-time license transfer and include revised clinical-trial expense estimates.
- Review clinical progress, trial timing, and safety and efficacy evidence for Pracinostat, ME-401, and ME-344.
- Monitor cash use, financing requirements, potential dilution, and contingent S*Bio and other contractual obligations.